Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

265.70DKK
28 Apr 2017
Change (% chg)

kr.-0.10 (-0.04%)
Prev Close
kr.265.80
Open
kr.265.50
Day's High
kr.266.50
Day's Low
kr.263.30
Volume
3,946,011
Avg. Vol
3,673,401
52-wk High
kr.384.80
52-wk Low
kr.218.20

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.43
Market Cap(Mil.): kr.521,453.31
Shares Outstanding(Mil.): 1,962.56
Dividend: 4.60
Yield (%): 2.86

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 17.76 29.08 30.08
EPS (TTM): 14.96 -- --
ROI: 75.08 13.73 13.25
ROE: 82.23 14.68 14.41

BRIEF-Novo Nordisk: FDA approves label update for obesity drug Saxenda

April 27 Danish drug maker Novo Nordisk A/S says:

Apr 27 2017

BRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk

* Xoma -on april 20, 2017 co received notice from Novo Nordisk a/s, relating to termination of exclusive license agreement with co due to strategic and business reasons

Apr 21 2017

BRIEF-Novo's once-weekly semaglutide shows consistent bloodglucose reductions

* Says once-weekly semaglutide demonstrated consistent bloodglucose reductions and weight loss regardless of background oral antidiabetic treatment

Apr 03 2017

BRIEF-Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the U.S

* Says has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the United States Food and Drug Administration (FDA)

Mar 29 2017

BRIEF-Novo Nordisk launches Fiasp-drug in Canada

* Says Fiasp, a new, fast-acting mealtime insulin for the treatmentof diabetes in adults, has been launched in Canada on Monday Further company coverage: (Reporting by Stine Jacobsen)

Mar 27 2017

EMA panel backs Novo Nordisk's hemophilia B drug

A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's hemophilia B drug.

Mar 24 2017

UPDATE 1-EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

Mar 24 2017

EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

Mar 24 2017

BRIEF-EU recommends approval of Novo Nordisk's haemophilia drug

* Recommends approval of Novo Nordisk's Nonacog Beta Pegol drug for treatment of haemophilia

Mar 24 2017

BRIEF-Novo Nordisk gets positive opinion for label update in EU for Tresiba

* The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials

Mar 24 2017

More From Around the Web

Earnings vs. Estimates